Mersana Therapeutics announces business updates, expected 2024 milestones

Mersana Therapeutics (MRSN) announced business updates, its expected 2024 milestones and its upcoming presentation at the 42nd Annual J.P. Morgan Healthcare Conference. Business Updates and Expected Milestones: XMT-1660: Mersana continues to advance its Phase 1 clinical trial of XMT-1660, the company’s lead Dolasynthen ADC candidate targeting B7-H4. Mersana plans to initiate tumor-specific expansion cohorts in the second quarter of 2024 and share initial dose escalation and backfill cohort data in mid-2024. XMT-2056: Mersana is restarting its Phase 1 clinical trial of XMT-2056, the company’s lead Immunosynthen ADC candidate targeting a novel HER2 epitope. The company plans to advance dose escalation in 2024. Additional Upcoming Data Presentations: In the first half of 2024, Mersana expects to present data at multiple scientific meetings demonstrating Dolasynthen’s differentiation from first-generation cytotoxic ADC platforms. The presentations will include clinical data from two discontinued ADC candidates, XMT-1592 and XMT-1536.Collaborations: Mersana continues to advance its collaborations with Janssen Biotech (JNJ) and Merck KGaA, (MKKGY) Darmstadt, Germany. Financial Resources: Mersana’s cash, cash equivalents and marketable securities as of September 30, 2023 were $241.0 million. The company continues to expect that its available funds will be sufficient to support its current operating plan commitments into 2026.